The present study revealed that although adenocarcinoma was the most common pathological type to be submitted for EGFR/ALK evaluation, patients with squamous carcinoma had an EGFR mutation rate of 8.3% and an ALK rearrangement rate of 3.7%. This evidence concerns the gene ALK and squamous cell carcinoma.